Pulse Biosciences to feature nPulse tech at Heart Rhythm Society meeting

Pulse Biosciences (PLSE) announced that its nPulse Cardiac Catheter will be prominently featured during the Heart Rhythm Society 2026 Annual Meeting, taking place April 23-26 in Chicago, Illinois. At HRS 2026, Pulse Biosciences will present late-breaking clinical trial updates, highlighting European feasibility study one-year outcomes of nanosecond PFA using a compliant catheter for the treatment of atrial fibrillation. The Company will also participate in a live case transmission during the PFA Live Case Summit. In addition to its booth and technology suite, the proprietary nsPFA Technology will be featured at several events at the HRS 2026 Annual Meeting including: Live Case Title: PVI+PWA Using Nanosecond PFA: This live case will demonstrate the use of Pulse Biosciences’ nsPFA technology in the treatment of atrial fibrillation, highlighting procedural workflow, lesion delivery, and real-time performance in a clinical setting. Presentation: One-year Outcomes of Nanosecond Pulsed Field Ablation Using a Compliant Catheter to Treat Atrial Fibrillation: A Multicenter Experience: This late-breaking presentation will report one-year clinical outcomes from a multicenter experience evaluating nanosecond pulsed field ablation using a compliant catheter to treat atrial fibrillation, contributing important longer-term data to the evolving PFA landscape.